PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8930576-4	1996	The substrates and inhibitors of CYP2C19 and CYP3A4 and the known genetic polymorphism of CYP2C19 explain some but not all of the interactions of lansoprazole, and particularly the interactions of omeprazole with carbamazepine, diazepam, phenytoin and theophylline or caffeine.	Theophylline	252-264	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51	
32657910-9	2020	The final model of theophylline clearance was as follows: CL/F (L/hr/kg) = 0.0484 x 1.40 x 0.861 x 0.889 x 0.557.Smoking is a well-known factor that markedly enhances CL/F through the induction of CYP1A enzymes, whereas CAM has been reported to inhibit CYP3A4.	Theophylline	19-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	253-259	
29063606-5	2018	Although CP studies are limited, meta-analysis-based reduction in CYP1A2, CYP2C19, and CYP3A4 enzyme abundances in a virtual oncology population effectively captures CP-PK for caffeine, theophylline, midazolam, simvastatin, omeprazole, and a subset of oncology compounds.	Theophylline	186-198	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-93	
11408986-7	2001	This case indicates that levofloxacin and clarithromycin inhibited theophylline metabolic pathways catalyzed by both CYP1A2 and CYP3A4 and resulted in the decrease in theophylline clearance.	Theophylline	67-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134	
11408986-7	2001	This case indicates that levofloxacin and clarithromycin inhibited theophylline metabolic pathways catalyzed by both CYP1A2 and CYP3A4 and resulted in the decrease in theophylline clearance.	Theophylline	167-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134	
9447218-3	1998	CYP3A4 and CYP1A2 enzymes are involved in drug interactions involving theophylline.	Theophylline	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6	
30762305-1	2019	This study provides whole-body physiologically-based pharmacokinetic models of the strong index cytochrome P450 (CYP)1A2 inhibitor and moderate CYP3A4 inhibitor fluvoxamine and of the sensitive CYP1A2 substrate theophylline.	Theophylline	211-223	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150	
7619673-12	1995	The results suggest that inter-individual variability in the inhibition of theophylline metabolism by ciprofloxacin can be attributed to inter-individual differences in the level of CYP1A2 expression and/or in the degree of inhibition of hepatic CYP1A2 and CYP3A4.	Theophylline	75-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	257-263